Two regulators, one gap Australia splits the job of regulating supply of medicines across two regulators, plus consumer law, which can act against misleading claims
The regulatory distinction you made is so crucial: the July FDA advisory committee meeting on BPC-157, TB-500, KPV, and others is about compounding access through the 503A pathway, not approval, and not evidence of efficacy
The authors identified TB4 as a potent wound healing factor with multiple complementary activities across the tissue repair cascade
Understanding the distinctions in absorption, effectiveness, convenience, and cost is key to making an informed decision with your healthcare provider
A heat map of this data was generated using only the genera and metabolites that had previously demonstrated significant main effects of treatment group (Fig
In this model, NO-related modulation may influence endothelial function and local microvascular stability